Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (181-190 of 377) with videos related to

Pageof 38
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an updateManfred Kaufmann, Gabriel N Hortobagyi, Aron Goldhirsch, et al.
Geburtshilfe Und Frauenheilkunde|June 25, 2021
Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert PanelTanja N Fehm, Elmar Stickeler, Peter A Fasching, et al.
NPJ Breast Cancer|April 7, 2023
Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapyJens Huober, Marion van Mackelenbergh, Andreas Schneeweiss, et al.
Annals of Surgical Oncology|February 25, 2026
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 StudySherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
Annals of Surgical Oncology|March 12, 2026
ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 StudySherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
JAMA Oncology|February 4, 2021
Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical TrialMattea Reinisch, Sabine Seiler, Tanja Hauzenberger, et al.
Breast Cancer Research and Treatment|February 14, 2015
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trialsCaterina Fontanella, Bianca Lederer, Stephan Gade, et al.
Geburtshilfe Und Frauenheilkunde|August 24, 2023
Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in HealthcareVolkmar Müller, Peter A Fasching, Naiba Nabieva, et al.
Geburtshilfe Und Frauenheilkunde|August 4, 2017
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017)Michael Untch, Jens Huober, Christian Jackisch, et al.
British Journal of Cancer|September 1, 2022
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO studyGuilherme Nader-Marta, Véronique Debien, Daniel Eiger, et al.
Pageof 38

Showing results (181-190 of 377) with videos related to

Sort By:
Pageof 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an updateManfred Kaufmann, Gabriel N Hortobagyi, Aron Goldhirsch, et al.
Geburtshilfe Und Frauenheilkunde|June 25, 2021
Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert PanelTanja N Fehm, Elmar Stickeler, Peter A Fasching, et al.
NPJ Breast Cancer|April 7, 2023
Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapyJens Huober, Marion van Mackelenbergh, Andreas Schneeweiss, et al.
Annals of Surgical Oncology|February 25, 2026
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 StudySherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
Annals of Surgical Oncology|March 12, 2026
ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 StudySherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
JAMA Oncology|February 4, 2021
Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical TrialMattea Reinisch, Sabine Seiler, Tanja Hauzenberger, et al.
Breast Cancer Research and Treatment|February 14, 2015
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trialsCaterina Fontanella, Bianca Lederer, Stephan Gade, et al.
Geburtshilfe Und Frauenheilkunde|August 24, 2023
Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in HealthcareVolkmar Müller, Peter A Fasching, Naiba Nabieva, et al.
Geburtshilfe Und Frauenheilkunde|August 4, 2017
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017)Michael Untch, Jens Huober, Christian Jackisch, et al.
British Journal of Cancer|September 1, 2022
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO studyGuilherme Nader-Marta, Véronique Debien, Daniel Eiger, et al.
Pageof 38